How Alnylam Pharmaceuticals (ALNY) Makes Money: A Visual Guide
Alnylam Pharmaceuticals (ALNY) generated $3.71B in revenue (TTM through Q4 2025), earning $313.75M in net profit (8.4% margin). Its largest revenue source is Product (70.3% of revenue). Below is an interactive breakdown of how revenue flows through the income statement.
Alnylam Pharmaceuticals (ALNY) Income Statement Flow
Frequently asked questions
How does Alnylam Pharmaceuticals (ALNY) make money?
- Alnylam Pharmaceuticals (ALNY) primarily makes money through Product, which accounts for 70.3% of total revenue. For TTM through Q4 2025, Alnylam Pharmaceuticals generated $3.71B in total revenue with a net profit margin of 8.4%.
What is Alnylam Pharmaceuticals (ALNY) gross profit margin?
- Alnylam Pharmaceuticals (ALNY) reported a gross profit margin of 81.7% for TTM through Q4 2025, equivalent to $3.03B in gross profit. This means Alnylam Pharmaceuticals retains 81.7% of each revenue unit after direct costs of production.
What is Alnylam Pharmaceuticals (ALNY) operating profit margin?
- Alnylam Pharmaceuticals (ALNY) reported an operating profit margin of 13.5% for TTM through Q4 2025, equivalent to $501.58M in operating profit. This reflects profitability after operating expenses such as R&D, sales, and administration, but before taxes and non-operating items.
What is Alnylam Pharmaceuticals (ALNY) net profit margin?
- Alnylam Pharmaceuticals (ALNY) reported a net profit margin of 8.4% for TTM through Q4 2025, equivalent to $313.75M in net profit. This is the share of revenue that remains as profit after all expenses, taxes, and non-operating items.
How much does Alnylam Pharmaceuticals (ALNY) invest in R&D?
- Alnylam Pharmaceuticals (ALNY) invested $1.32B in research and development in TTM through Q4 2025 (35.5% of total revenue). R&D spending reflects investment in future products, services, and technologies.
How much does Alnylam Pharmaceuticals (ALNY) spend on capital expenditures?
- Alnylam Pharmaceuticals (ALNY) spent $58.70M on capital expenditures in TTM through Q4 2025 (1.6% of total revenue). Capital expenditures represent investments in physical assets such as property, equipment, and infrastructure.
What is Alnylam Pharmaceuticals (ALNY) free cash flow?
- Alnylam Pharmaceuticals (ALNY) generated $465.38M in free cash flow for TTM through Q4 2025 (12.5% of total revenue). Free cash flow is the cash remaining after capital expenditures and represents the company's ability to fund growth, pay dividends, or reduce debt.
What is Alnylam Pharmaceuticals (ALNY) effective tax rate?
- Alnylam Pharmaceuticals (ALNY) had an effective tax rate of 2.9% for TTM through Q4 2025. This is the actual percentage of pre-tax income paid as income taxes.
About this data
- What is a Sankey diagram?
- A Sankey diagram shows how money flows through a company from revenue to net profit. The width of each flow represents its proportion.
- How is the data calculated?
- We use the income statement from company filings. For TTM (Trailing Twelve Months), we sum the last four quarters. Revenue flows to cost of revenue and gross profit, then to operating expenses (R&D, S&M, G&A) and operating profit.
- When was this data last updated?
- Based on company filings through TTM through Q4 2025.